{'52WeekChange': -0.23952746,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Sovereign House',
 'address2': 'Vision Park Chivers Way Histon',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 126.09,
 'askSize': 1100,
 'averageDailyVolume10Day': 297712,
 'averageVolume': 349271,
 'averageVolume10days': 297712,
 'beta': 1.940056,
 'beta3Year': None,
 'bid': 125.83,
 'bidSize': 1200,
 'bookValue': 23.032,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 127.94,
 'dayLow': 123.53,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -53.398,
 'enterpriseToRevenue': 8.811,
 'enterpriseValue': 3460321024,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '44 1223 235 667',
 'fiftyDayAverage': 128.44771,
 'fiftyTwoWeekHigh': 175.35,
 'fiftyTwoWeekLow': 67.98,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 30361241,
 'forwardEps': 2.19,
 'forwardPE': 57.61187,
 'fromCurrency': None,
 'fullTimeEmployees': 901,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01116,
 'heldPercentInstitutions': 0.83334,
 'industry': 'Drug Manufacturers—General',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/gwpharm.com',
 'longBusinessSummary': 'GW Pharmaceuticals plc, a biopharmaceutical company, '
                        'focuses on discovering, developing, and '
                        'commercializing cannabinoid prescription medicines '
                        'using botanical extracts derived from the Cannabis '
                        'plant. Its lead product is Epidiolex, an oral '
                        'medicine for the treatment of refractory childhood '
                        'epilepsies, as well as for the treatment of Dravet '
                        'syndrome, Lennox-Gastaut syndrome, tuberous sclerosis '
                        'complex, and infantile spasms. The company also '
                        'develops and markets Sativex, an oromucosal spray for '
                        'the treatment of spasticity due to multiple '
                        'sclerosis. In addition, it develops various product '
                        'candidates for the treatment of glioblastoma, '
                        'neonatal hypoxic-ischemic encephalopathy, and '
                        'schizophrenia. Further, the company has license and '
                        'development agreements with Almirall S.A.; Bayer '
                        'HealthCare AG; Ipsen Biopharm Ltd; and Neopharm '
                        'Group. It primarily operates in Europe, the United '
                        'Kingdom, the United States, Canada, and Asia. GW '
                        'Pharmaceuticals plc was founded in 1998 and is based '
                        'in Cambridge, the United Kingdom.',
 'longName': 'GW Pharmaceuticals plc',
 'market': 'us_market',
 'marketCap': 3884849920,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_6136592',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 33080000,
 'nextFiscalYearEnd': 1640908800,
 'open': 127.6,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.09,
 'phone': '44 1223 266 800',
 'previousClose': 129,
 'priceHint': 2,
 'priceToBook': 5.4780307,
 'priceToSalesTrailing12Months': 9.892212,
 'profitMargins': 0.084230006,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 127.94,
 'regularMarketDayLow': 123.53,
 'regularMarketOpen': 127.6,
 'regularMarketPreviousClose': 129,
 'regularMarketPrice': 127.6,
 'regularMarketVolume': 362028,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 31079700,
 'sharesPercentSharesOut': 0.14140001,
 'sharesShort': 4393740,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4478324,
 'shortName': 'GW Pharmaceuticals Plc',
 'shortPercentOfFloat': None,
 'shortRatio': 15.67,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'GWPH',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 1.065,
 'trailingPE': 118.469475,
 'twoHundredDayAverage': 112.5254,
 'volume': 362028,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.gwpharm.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'CB24 9BZ'}